Immunotherapy combo may boost liver cancer ablation outcomes

NCT ID NCT06045975

Ongoing Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether giving two immunotherapy drugs (durvalumab and tremelimumab) before and after a standard ablation procedure can help prevent liver cancer from returning. Thirty adults with early-stage liver cancer will receive one infusion of the drug combination, then undergo ablation, followed by 11 monthly infusions of durvalumab alone. The main goal is to see how long patients stay free of local recurrence.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Durvalumab and Tremelimumab (immunotherapy drugs)
What this could lead to: If it works, this could offer a new way to reduce the chance of liver cancer coming back after ablation treatment.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. Immunotherapy can cause serious side effects like inflammation of organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC - HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Hospitl Avicenne

Bobigny, 93000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.